Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients



Status:Recruiting
Conditions:Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:1/23/2019
Start Date:May 4, 2018
End Date:December 2020
Contact:Clinical Study Manager
Email:bayda.bahur@prometheuslabs.com
Phone:858 587 4107

Use our guide to learn which trials are right for you!

To evaluate the relationship between noninvasive biomarkers (patient serological markers and
metagenomic analysis of stool) and disease status as determined by colonoscopy and by
clinical symptoms in patients with Crohn's disease, and to evaluate whether changes in the
biomarker levels over time correlate to changes in the state of patients' disease.


Inclusion Criteria:

1. Males and females with CD who are 18 years of age or older on the date of obtaining
informed consent and are undergoing a colonoscopy at the study site.

2. The patient must have a confirmed diagnosis of CD based on results a complete medical
evaluation and the assessment by a physician specialized in inflammatory bowel
disease.

3. All CD patients should have no evidence for another active organic disease of the GI
tract or medical problems as specified below in the exclusion criteria.

4. All patients must have a colonoscopic examination performed preferably on the same day
as blood specimen is drawn, or blood may be drawn up to one week prior to colonoscopy.
Stool specimen will be collected prior to the beginning of bowel prep for the
colonoscopy, up to 10 days prior to bowel prep.

5. Understand the procedures and requirements of the study by providing written informed
consent including consent and authorization for protected health information
disclosure.

Exclusion Criteria:

1. Extensive small bowel resection or short bowel syndrome.

2. Surgery for CD within the 6 months previous to enrollment.

3. Receipt of any blood products within 3 months prior to study entry.

4. Known pregnancy or breast feeding within 3 months of specimen collection.

5. Recent history of viral or bacterial gastroenteritis including Clostridium difficile
infection < 4 weeks prior to the blood draw

6. Concurrent diagnosis of another currently active erosive GI mucosal disease such as
erosive esophagitis, gastric or duodenal ulcer, celiac sprue, diverticulitis, etc.

7. History of intestinal or colorectal cancer, of active autoimmune diseases, or of other
chronic uncontrolled systemic disorders

8. History of bowel prep within the past 3 months.

9. History of alcohol or substance abuse.

10. History of prior colectomy or stricturing disease that could limit colonoscopy
examination of small bowel mucosa.

11. Current ostomy or ileoanal pouch.

12. Current or previous (of less than 4 weeks prior) participation in in a clinical trial
for an investigational drug.
We found this trial at
6
sites
Brockton, Massachusetts 02302
Principal Investigator: Jerry Stern, MD
Phone: 508-588-9900
?
mi
from
Brockton, MA
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
Principal Investigator: Caroline Hwang, MD
Phone: 323-442-6151
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Douglas Wolf, MD
Phone: 404-257-9000
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hamden, Connecticut 06518
Principal Investigator: Philip Ginsburg, MD
Phone: 203-281-5161
?
mi
from
Hamden, CT
Click here to add this to my saved trials
8701 W Watertown Plank Rd
Milwaukee, Wisconsin
(414) 955-8296
Principal Investigator: Andres Yarur, MD
Phone: 414-805-7181
Medical College of Wisconsin The Medical College (MCW) of Wisconsin is a major national research...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Ventura, California 93003
Principal Investigator: Sabine Hazan, MD
Phone: 805-339-0549
?
mi
from
Ventura, CA
Click here to add this to my saved trials